Nomura Holdings Inc. Reduces Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Nomura Holdings Inc. decreased its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 99.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,000 shares of the company’s stock after selling 2,712,500 shares during the quarter. Nomura Holdings Inc.’s holdings in Teva Pharmaceutical Industries were worth $157,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of TEVA. FMR LLC grew its holdings in shares of Teva Pharmaceutical Industries by 3,553.8% in the third quarter. FMR LLC now owns 2,564,339 shares of the company’s stock valued at $26,156,000 after purchasing an additional 2,494,156 shares during the period. Clal Insurance Enterprises Holdings Ltd grew its holdings in shares of Teva Pharmaceutical Industries by 7.1% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 32,804,131 shares of the company’s stock valued at $342,788,000 after purchasing an additional 2,188,212 shares during the period. Meitav Investment House Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 82.8% in the fourth quarter. Meitav Investment House Ltd. now owns 4,305,674 shares of the company’s stock valued at $44,914,000 after purchasing an additional 1,950,500 shares during the period. Migdal Insurance & Financial Holdings Ltd. lifted its position in Teva Pharmaceutical Industries by 6.9% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,919,540 shares of the company’s stock valued at $301,920,000 after buying an additional 1,860,000 shares during the last quarter. Finally, Glenview Capital Management LLC acquired a new position in Teva Pharmaceutical Industries in the fourth quarter valued at about $16,752,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 2.8 %

Shares of NYSE:TEVA opened at $16.49 on Tuesday. The firm’s 50 day moving average price is $15.72 and its 200 day moving average price is $13.52. The stock has a market cap of $18.67 billion, a price-to-earnings ratio of -40.21, a price-to-earnings-growth ratio of 1.63 and a beta of 0.91. Teva Pharmaceutical Industries Limited has a fifty-two week low of $7.42 and a fifty-two week high of $17.69. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.20.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, May 8th. The company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.03). The firm had revenue of $3.82 billion during the quarter, compared to analyst estimates of $3.70 billion. Teva Pharmaceutical Industries had a negative net margin of 2.88% and a positive return on equity of 37.33%. As a group, equities research analysts predict that Teva Pharmaceutical Industries Limited will post 2.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on TEVA. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 target price on the stock in a research report on Friday, March 8th. Piper Sandler reaffirmed an “overweight” rating and issued a $20.00 target price (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, May 13th. StockNews.com cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Monday, May 20th. Bank of America upped their target price on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday, May 30th. Finally, Barclays increased their price target on shares of Teva Pharmaceutical Industries from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 5th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.88.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Vikki L. Conway sold 15,219 shares of the stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $16.74, for a total value of $254,766.06. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 15,500 shares of the stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $16.80, for a total value of $260,400.00. Following the transaction, the chief accounting officer now directly owns 17,814 shares in the company, valued at $299,275.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Vikki L. Conway sold 15,219 shares of the stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The disclosure for this sale can be found here. Insiders have sold a total of 549,719 shares of company stock valued at $9,353,736 over the last 90 days. 0.55% of the stock is owned by corporate insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.